Polymorphism in tumor necrosis factor genes associated with myasthenia gravis

Journal of Neuroimmunology

Volumn 88, Issue 1-2, 1998, Pages 137-143

  Hjelmstrom P ^a   Peacock, C S ^b   Giscombe, R ^a   Pirskanen, R ^c   Lefvert, A K ^a   Blackwell, J M ^b   Sanjeevi, C B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

HLA; Lymphotoxin; Myasthenia gravis; TNF

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; HAPLOTYPE; HUMAN; HUMAN TISSUE; INTRON; MYASTHENIA GRAVIS; ONSET AGE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0032146353     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00107-6     Document Type: Article

References (33)

1. Abraham, L.J., Du, D.C., Zahedi, K., Dawkins, R.L., Whitehead, A.S., 1991. Haplotypic polymorphisms of the TNF-β gene. Immunogenetics 33, 50-53.
2. Abraham, L.J., French, M.A.H., Dawkins, R.L., 1993. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin. Exp. Immunol. 92, 14-18.
3. Badenhoop, K., Schwartz, G., Trowsdale, J., Lewis, V., Gale, E.A.M., Botazzo, G.F., 1989. TNF-α gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32, 445-449.
4. Begovich, A.B., McClure, G.R., Suraj, V.C., Helmuth, R.C., Fildes, N., Bugawan, T.L., Erlich, H.A., Klitz, W., 1992. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J. Immunol. 148, 249-258.
5. Bendtzen, K., Morling, N., Fomsgaard, A., Svenson, M., Jakobsen, B., Odum, A., Svejgaard, A., 1988. Association between HLA-DR2 and production of tumour necrosis factor a and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand. J. Immunol. 28, 599-605.
6. Cabrera, M., Shaw, M.-A., Sharples, C., Williams, H., Castes, M., Convit, J., Blackwell, J.M., 1995. Polymorphisms in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 182, 1259-1264.
7. Campbell, R.D., Trowsdale, J., 1993. Map of the human MHC. Immunol. Today 14, 349-352.
8. Compston, D.A.S., Vincent, A., Newsom-Davis, J., Batchelor, J.R., 1980. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103, 579-601.
9. Confalonieri, P., Antozzi, C., Cornelio, F., Simoncini, O., Mantegazza, R., 1993. Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon-γ and tumor necrosis factor-α levels in patients' serum. J. Neuroimmunol. 48, 33-36.
10. Crouau-Roy, B., Brient, L., Bouissou, C., Stavropoulos, C., Poicot, F., Cambon-Thomsen, A., Clayton, J., 1993. Tumor necrosis factor microsatellites in four European populations. Hum. Immunol. 38, 213-216.
11. Degli-Esposti, M.A., Andreas, A., Christiansen, F.T., Schalke, B., Albert, E., Dawkins, R.L., 1992. An approach to the localization of the susceptibility genes for general myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 35, 355-364.
12. Drachman, D.B., 1994. Myasthenia gravis. N. Eng. J. Med. 330, 1797-1810.
13. Garcia-Merino, A., Alper, C.A., Usuku, K., Marcus-Bagey, D., Lincoln, R., Awdeh, Z., Yunis, E.J., Eisenbarth, G.S., Brink, S.J., Hauser, S.L., 1996. Tumor necrosis factor (TNF) in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex and TNF secretion. Hum. Immunol. 50, 11-21.
14. Greenberg, S.J., Fujihara, K., Selkirk, S.M., Yu, F., Du, T.-L., Glenister, N., Hohmann, P., Rickert, M.H., Spence, P.O., Miller, C.E., Jacobs, L.E., 1997. Novel compound tetra-, dinucleotide microsatellite polymorphism in the tumor necrosis factor/lymphotoxin locus. Clin. Diag. Lab. Immunol. 4, 79-84.
15. Gu, D., Wogensen, L., Calcutt, N.A., Xia, G., Zhu, S., Merlie, J.P., Fox, H.S., Lindstrom, J., Powell, H.C., Sarvetnick, N., 1995. Myasthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J. Exp. Med. 181, 547-555.
16. Hjelmström, P., Giscombe, R., Lefvert, A.K., Pirskanen, R., Kockum, I., Landin-Olsson, M., Sanjeevi, C.B., 1995. Different HLA-DQ are positively and negatively associated in Swedish patients with myasthenia gravis. Autoimmunity 22, 59-65.
17. Hjelmström, P., Giscombe, R., Lefvert, A.K., Pirskanen, R., Kockum, I., Landin-Olsson, M., Sanjeevi, C.B., 1996. Domains of polymorphic amino acids in the HLA-DQ molecule are associated with disease heterogeneity in myasthenia gravis. J. Neuroimmunol. 65, 125-131.
18. Hjelmström, P., Giscombe, R., Lefvert, A.K., Grünewald, J., Pirskanen, R., Kockum, I., Landin-Olsson, M., Sanjeevi, C.B., 1997a. HLA-DQ associations and T-cell receptor V-gene usage in peripheral blood from Swedish myasthenia gravis patients. Eur. J. Immunogenet. 24, 179-189.
19. Hjelmström, P., Giscombe, R., Lefvert, A.K., Pirskanen, R., Kockum, I., Landin-Olsson, M., Sanjeevi, C.B., 1997b. TAP polymorphisms in Swedish myasthenia gravis patients. Tissue Antigens 49, 176-179.
20. Jacob, C.O., Fronek, Z., Lewis, G.D., Koo, M., Hansen, J.A., McDevitt, H.O., 1990. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A. 87, 1233-1238.
21. Jongeneel, C.V., Briant, L., Udalova, A., Sevin, A., Nedospasov, S.A., Cambon-Thomsen, A., 1991. Extensive polymorphism in the human-tumor necrosis factor region and relation to extended HLA haplotypes. Proc. Natl. Acad. Sci. U.S.A. 88, 9717-9721.
22. Kratz, A., Campos-Neto, A., Hanson, M.S., Ruddle, N.H., 1996. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J. Exp. Med. 183, 1461-1472.
23. Matusevicius, D., Navikas, V., Palasik, W., Pirskanen, R., Fredriksson, S., Link, H., 1996. Tumor necrosis factor-alpha, lymphotoxin, interleukin (Il)-6, Il-10, Il12 and perform mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia. J. Neuroimmunol. 71, 191-198.
24. Messer, G., Spengler, U., Jung, M.C., Honold, G., Blömer, K., Pape, G.R., Rietmuller, G., Weiss, E.H., 1991. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-β gene correlates with a variant amino acid in position 26 and a reduced level of TNF-β production. J. Exp. Med. 173, 209-219.
25. Monos, D.S., Kamoun, M., Udalova, I.A., Csanky, W., Cizman, B., Turetskaya, R.L., Smirnova, J.B., Zharkov, V.G., Gasser, D., Zmijewski, C.M., Spielman, R.S., Nedospasov, S.A., 1995. Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus: Linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Hum. Immunol. 44, 70-79.
26. Murphy, M., Friend, D.S., Pike-Nobile, L., Epstein, L.B., 1992. Tumor necrosis factor-α and IFN-γ expression in human thymus. J. Immunol. 149, 2506-2512.
27. Nedospasov, S.A., Udalova, I.A., Kuprash, D.V., Turetskaya, R.L., 1991. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. J. Immunol. 147, 1053-1059.
28. Pociot, F., Briant, L., Jongeneel, C.V., Mölvig, J., Worsaae, H., Abbal, M., Thomsen, M., Nerup, J., Combon-Thomsen, A., 1993. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur. J. Immunol. 23, 224-231.
29. Ruddle, N.H., 1992. Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr. Opin. Immunol. 4, 327-332.
30. Sanjeevi, C.B., Seshiah, V., Möller, E., Olerup, O., 1992. Different genetic backgrounds for malnutrition-related diabetes and Type 1 (insulin-dependent) diabetes mellitus in South Indians. Diabetologia 35, 283-286.
31. Svejgaard, A., Ryder, L., 1994. HLA and disease associations: detecting the strongest association. Tissue Antigens 43, 18-27.
32. Vieira, M.L., Caillat-Zucman, S., Gajdos, P., Cohen-Kaminsky, S., Casteur, A., Bach, J.-F., 1993. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J. Neuroimmunol. 47, 115-122.
33. Vincent, A., 1994. Aetiological factors in development of myasthenia gravis. Adv. Neuroimmunol. 4, 355-371.